Sangamo Biosciences, Inc.  

(Public, NASDAQ:SGMO)   Watch this stock  
Find more results for SGMO
5.00
+0.18 (3.73%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.78 - 5.04
52 week 4.08 - 9.91
Open 4.80
Vol / Avg. 0.00/901,907.00
Mkt cap 366.28M
P/E     -
Div/yield     -
EPS -0.94
Shares 70.62M
Beta 2.42
Inst. own 67%
Oct 26, 2016
Q3 2016 Sangamo BioSciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 9, 2016
Sangamo BioSciences Inc at Biocentury NewsMakers in the Biotech Industry
Sep 7, 2016
Sangamo BioSciences Inc at Wells Fargo Securities Healthcare Conference
Aug 16, 2016
Sangamo BioSciences Inc at Wedbush PacGrow Healthcare Conference - Webcast
Aug 3, 2016
Q2 2016 Sangamo BioSciences Inc Earnings Call
Aug 3, 2016
Q2 2016 Sangamo BioSciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -717.86% -102.94%
Operating margin -725.07% -118.51%
EBITD margin - -116.01%
Return on average assets -56.40% -17.68%
Return on average equity -62.81% -20.40%
Employees 119 -
CDP Score - -

Address

Point Richmond Tech Center II 501 Canal Blvd
RICHMOND, CA 94804
United States - Map
+1-510-9706000 (Phone)
+1-510-2368951 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics. Its ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. It has preclinical programs in hemophilia A and Lysergic acid diethylamide and research stage programs in monogenic diseases, including certain central nervous system disorders and cancer immunotherapy.

Officers and directors

Alexander Macrae President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
H. Ward Wolff Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President
Age: 67
Bio & Compensation  - Reuters
Geoffrey M. Nichol Executive Vice President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Dale G. Ando M.D. Vice President - Therapeutic Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Edward O. Lanphier II Non-Executive Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
H. Stewart Parker Director
Age: 59
Bio & Compensation  - Reuters
William R. Ringo Jr. Director
Age: 69
Bio & Compensation  - Reuters
Stephen George Dilly Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
John W. Larson Independent Director
Age: 80
Bio & Compensation  - Reuters